Immunis Inc., a groundbreaking biotech developing novel secretome therapeutics for age-related diseases and immune dysfunction, is thrilled to announce that its esteemed Chairman, Dr. Hans Keirstead, will be presenting at the Festival of Biologics in San Diego. This renowned conference serves as a global platform for leading minds in the biologics sector to share breakthroughs, foster collaborations, and discuss the future of biotechnology and medicine.

A current challenge with metabolism-boosting drugs for weight-loss is the concurrent loss of muscle mass. Healthy muscle is key to maintaining independence and quality of life with age, but there are no treatments to address muscle atrophy or reverse sarcopenia. At the heart of Immunis’ groundbreaking research is IMMUNA, a novel therapeutic with the potential to become the first drug in the world to enhance metabolism while promoting muscle growth. Preliminary human data from our Phase 1/2a clinical trial is strongly supportive of our pre-clinical results in rodents.

Immunis’ recently published preclinical results in Aging Cell delineating how IMMUNA can beneficially impact muscle function and metabolism. The research provides compelling evidence of IMMUNA’s ability to increase lean body mass, reduce fat mass, and enhance muscle quality in aged mouse models, marking a major leap forward in our understanding of treating age-related physical decline.

Looking to the future, the potential applications of IMMUNA as a therapy are vast and promising. By targeting the root causes of age-related muscle and metabolic decline, IMMUNA stands on the precipice of offering a transformative solution for extending healthspan, improving quality of life, and addressing the unmet needs of millions affected by muscle atrophy. Immunis remains committed to advancing IMMUNA as an innovative therapeutic, ushering in a new era of age-related disease management and immune rejuvenation.

About Immunis Inc.

Immunis is a private biotechnology company developing a novel immunomodulatory secretome product for the various manifestations of age and disease-related immune decline. The investigational product line leverages Immunis’ leading-edge capabilities in secretome technology to deliver a product of all natural, all human immune modulators in their natural relative physiological concentrations. For additional information about Immunis’ Phase 1/2a clinical trial please visit: https://immunisbiomedical.com/clinical-trials/

Cautionary Note Regarding Forward-Looking Statements

This communication contains statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as applicable. Forward-looking statements include, but are not limited to, statements regarding our plans, beliefs, expectations and assumptions, as well as other statements that are not necessarily historical facts. You are cautioned that these forward-looking statements are only predictions and involve risks and uncertainties. Further, any forward-looking statement speaks only as of the date as of which it is made, and we do not intend to update or revise any forward-looking statements. This communication also contains market data related to our business and industry which includes projections that are based on several assumptions we believe are reasonable and most significant to the projections as of the date of this communication. If any of our assumptions prove to be incorrect, our actual results may significantly differ from our projections based on these assumptions. This communication is neither an offer to sell nor a solicitation of an offer to buy any of the securities described herein.

Contact email: contact@immunisbiomedical.com